The East of England IRC is working together with i10 to help facilitate access to intellectual property and technologies developed by the East of England's 10 Higher Education Institutions - Anglia Ruskin University, Cranfield University, Norwich School of Art and Design, University of Cambridge, University of East Anglia, University of Essex, University of Hertfordshire, University of Luton, The Open University and Writtle College.

Back to top

Cambridge University

• A fast assay for measuring the activity of glycosaminoglycan (GAG) lyases (depolymerases) (Reference: 08 GB EAST 0JIC)
  A UK university has developed a fast assay for determining the activity of glycosaminoglycan lyases. This will open their potential in research and clinical use, including in neural injuries and mucopolysaccharidosis. Manufacturers of enzymatic assay kits are sought for licensing and joint development.
  
  
• An endometriosis mouse model that mimics the development of the human disease (Reference: 07 GB EAST 0J5Z)
  A research group at a UK university has developed an endometriosis mouse model that, unlike existing ones, produces viable endometriosis-like lesions. This 'human condition' model will be useful in screening and identifying drug compounds, investigating the pathogenesis of endometriosis and identifying target genes or others factors associated with it. Biotech and pharma partners are sought for licensing and further development.
  
  
• Improved Cell Culture System for Adipocytes (Fat Cells) (Reference: 07 GB EAST 0IWU)
  A UK university has developed a method for making 3D cell culture systems for adipocytes (fat cells). The cells closely simulate morphological characteristics and behaviour as in vivo. They can be grown in sufficient numbers and manipulated easily (unlike the conventional cell cultures). The method is available for license for cell culture products and systems suppliers. Research groups in obesity, diabetes and inflammation are invited for joint R&D.
  
  
• Generation of Clinical-Grade Multi-Lineage Progenitor Cells from Human Pluripotent Cells (Reference: 07 GB EAST 0IG4)
  A research group at a UK university has developed a novel means of propagating pluripotent cells and generating neuroectoderm, endoderm and mesoderm progenitor cells using humanised chemically defined media with differentiation factors. Partners for licensing and further development are sought.
  
  
• A Scaleable and Defined System for Generating Clinical Grade Neural Stem Cells from Human Embryonic Stem Cells (Reference: 07 GB EAST 0IFO)
  A research group at a UK university has developed a novel, scaleable and widely applicable system for deriving and propagating neural precursor cells from human embryonic stem cells without the use of animal products, proprietary formulations or genetic manipulation. Partners for licensing and further development are sought.
  
  
• Method of Production of Pluripotent Stem Cells in a Wide Range of Mammalian Species (Reference: 07 GB EAST 0IG6)
  A research group at a UK university has developed a novel method for the generation of mammalian pluripotent stem cells. The method has been proven in man, rat and mouse and should be readily adaptable to a wide range of mammalian species. Partners for licensing and further development are sought.
  
  
• Stimulation of Neuronal Regeneration and Repair by Human a9ß1 Integrin (Ref: 07 GB EAST 0HFY)
  Researchers at a university in the East of England have shown that human a9ß1 integrin mediates axon outgrowth and Schwann cell migration, and offers excellent possibilities for neuronal regeneration and repair within the central nervous system, including spinal cord injury, brain injury, multiple sclerosis and neurodegenerative diseases. The university is seeking commercial partners for licensing, collaboration and development of this technology.
  
  
• A fast, efficient and low-cost process for the production of high-purity carbon-encapsulated magnetic nanoparticles (CEMNs) (Reference: 07 GB EAST 0HU8)
  A UK university has developed a simple and relatively low-temperature (~1000°C) one-step process for the production of high-purity carbon-encapsulated magnetic nanoparticles (CEMNs). The scalable process uses cheap, non-toxic, easy-to-handle raw materials, employs simple equipment, and in contrast to existing production methods produces yields of encapsulated particles close to 100%. The university is looking for partners for further development and licensing.
  
  
• Novel algorithms for object recognition and image matching (Reference: 06 GB EAST 0G8P)
  Researchers at a university in the East of England have developed a novel set of algorithms that allow fast comparison between images of complex objects even when there are differences in viewpoint and/or illumination. The technology can be applied in applications such as robot navigation, aerial searching and trademark searching. The university is looking for partners for further development and licensing.
  
  
• Self-cleaning surface coatings (Reference: 06 GB EAST 0GDI)
  Researchers at a university in the East of England have developed a coating technique that can be used to create self-cleaning surfaces. The university is looking for partners for joint further development and/or licensing of this technology.
  
  
• Novel mouse model of advanced vulnerable Atherosclerosis (Reference: 06 GB EAST 0G3C)
  Researchers at a University in the East of England have engineered transgenic mice that can develop a disease state that shares major features of advanced vulnerable atherosclerosis in humans. This valuable model is highly suited to studies of cardiovascular drugs and the long term study of arterial diseases. The University is looking for pharmaceutical and biotechnology companies to license the technology.
  
  

• Novel Method for Forming of Ductile Metal into Difficult Shapes (Reference: 06 GB EAST 0FW5)
  A university in the East of England has developed a flexible, high-performance route to forming shapes in ductile sheet materials. The method employs simple and cheap tools and standard CNC machines, offers high deformation and low residual stresses, and can be applied to sheet, tube and other geometries. The technology is available for trials, and the university is looking for commercial companies for possible joint further development and/or licensing.
  

• New collagen peptides (Reference: 06 GB EAST 0FMO)
  Researchers at a university in the East of England have developed synthetic collagen peptides useful in modulating platelet aggregation and activation. Potential applications include diagnostic reagents to explore platelet function and thrombus formation, coating wounds and implants to stimulate clotting. The university is looking for commercial partners for licensing, collaboration and development of these technologies.
  

• Cognitive testing device for rodents (Reference: 06 GB EAST 0FMQ)
  Researchers at a university in the East of England have developed a tool for cognitive screening of pharmacological, transgenic and knockout rodent models that is high-throughput, non-aversive, standardisable and easily implementable. The university is seeking commercial partners for licensing, collaboration and development of this technology.
  

• Novel protein for diagnostics and treatment of cancer, autoimmunity and viral infection (Reference: 05 GB EAST 0DNT)
  Researchers at the University of Cambridge have identified and characterised a novel member of the RAET1/ULBP family of proteins, termed 'RAET1G', which has great potential for novel diagnostic tests (e.g. tumour markers) and modulation of RAET1G activity for treatment of diseases such as cancer, autoimmunity and viral infection. The university is seeking to establish collaboration and licensing relationships for commercialisation of this exciting technology.

• New Target for development of anti-cancer combination therapies (Reference: 06 GB EAST 0FG0)
  Researchers at a university in the East of England have discovered a method to sensitise tumour cells to treatment with certain key drugs used in chemotherapy that has great potential for the development of combination therapies for the treatment of cancer. The university is looking to establish collaboration and licensing relationships with pharmaceutical or biotechnology companies for the commercialisation of this technology.
  
  
• Novel enzyme system for the formation of new DNA molecules (ligation) (Reference: 06 GB EAST 0FGT)
  Researchers at a university in the East of England have discovered a novel enzyme system that catalyses the formation of new DNA molecules from one or more fragments with much higher efficiency than existing enzymes. It has a range of other activities and has great potential to be a powerful new tool for molecular biologists. The university is looking for collaboration and licensing relationships with pharmaceutical or biotechnology companies for commercialisation of this technology.
  
  
• New target to block the reproduction of cancer cells (Reference: 06 GB EAST 0FGU)
  Researchers at a university in the East of England have discovered a method to reduce reproduction of cancer cells and make them more sensitive to some of the key drugs used in chemotherapy. The method has great potential for improving the responsiveness of cancer cells to treatment with such drugs and the subsequent development of combination therapies for treatment of cancer. The university is looking for collaboration and licensing relationships with pharmaceutical or biotechnology companies.
  
  
• New target to enhance the effectiveness of anti-cancer drugs (Reference: 06 GB EAST 0FGM)
  Researchers at a university in the East of England have identified a novel molecular target to make cancer cells more sensitive to some of the key drugs that are used in chemotherapy. The university is looking for collaboration and licensing relationships with pharmaceutical or biotechnology companies for commercialisation of this technology.
  
  
• Technique for the assessment and treatment of kidney disease (Reference: 05 GB EAST 0DLQ)
  Researchers at the University of Cambridge have discovered that a specific protein (Tumour Necrosis Factor) that plays a major role in chronic inflammatory immune-mediated disorders can be manipulated in a way that shows great potential for the assessment and treatment of kidney diseases associated with inflammation or ischemia (decrease in blood supply to an organ). The university wishes to establish collaboration and licensing relationships for the commercialisation of this exciting technology
  
  

• Novel technologies for the delivery of genes in gene therapy (Reference: 05 GB EAST 0DLO)
  Researchers at the University of Cambridge have developed a series of effective technologies for delivery of genes in gene therapy, based on so-called lentiviral vectors. These have extensive intellectual property protection including granted US patents. The university is looking for collaboration and licensing relationships for the commercialisation of this exciting technology.

• Phyto-remediation of metal-contaminated land: A low-cost in-situ organo-zeolitic-soil system (Reference: 05 GB EAST 0CIF)
  Researchers at universities in the UK and France, together with a Canadian SME have developed an organo-zeolitic-soil technology that promotes the sustained growth of plants on soils that are heavily contaminated by metal wastes. The technology is low-cost, functions in-situ and requires only a simple surface amendment with this natural mineral-organic mixture. Partners are sought to bring the technology to market through a licensing agreement, joint venture or through technical collaboration.

Back to top

Anglia Ruskin University

Back to top

Cranfield University

Back to top

Open University

Disclaimer
The information contained throughout this website is provided for convenience as part of the services we offer. However, we cannot accept any liability for its accuracy or content. Visitors who rely on this information do so entirely at their own risk.